Cardiomyopathy Trial, Recruiting NCT06730464 Sponsor: Centro Medico Teknon Condition: Cardiomyopathy
Back to Cardiomyopathy

Cardiomyopathy Trial, Recruiting

NCT06730464
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a non-ischemic heart condition affecting the left side of your heart, specifically dilated cardiomyopathy (an enlarged heart), non-dilated left ventricular cardiomyopathy (a heart muscle disease without enlargement), or cardiomyopathy that developed after myocarditis (heart inflammation).
  • Doctors expect you to live for more than 1 year and you are generally able to carry out daily activities.
  • You have already had at least one special heart MRI scan using a contrast dye called gadolinium (known as LGE-CMR).
  • You had not experienced any serious abnormal heart rhythms at the time of your first LGE-CMR scan.
  • You are willing and able to sign a consent form agreeing to take part in the study.

Who may not be able to join:

  • You are currently pregnant.
  • Your life expectancy is less than 1 year, or your heart condition is so severe that you are unable to carry out any physical activity without discomfort (confirm with trial site).
  • You have another type of heart condition at the same time, such as heart disease caused by blocked arteries, a congenital (birth-related) heart defect, or a specific condition affecting the right side of the heart.
  • You have not had the special gadolinium heart MRI scan, or the results from that scan are not available.
  • You had already experienced a serious abnormal heart rhythm before or at the time of your first gadolinium heart MRI scan.
  • You are already taking part in another experimental medical treatment or trial.
  • There are personal, geographical, or social reasons that would make it difficult for you to participate, or you are unwilling or unable to sign the consent form.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centro Medico Teknon
Registry
ClinicalTrials.gov
Start date
7 October 2024
Est. completion
30 October 2026

Where this trial is recruiting

🇮🇹 Italy 🇵🇹 Portugal 🇪🇸 Spain

Primary endpoints

Number of patients presenting one of sudden cardiac death, sustained ventricular arrhythmia, or defibrillator therapy.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov